title: Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.
abstract: Respiratory infection with Burkholderia cenocepacia is associated with accelerated decline in lung function and increased mortality in cystic fibrosis (CF) patients (A. M. Jones, M. E. Dodd, J. R. W. Govan, V. Barcus, C. J. Doherty, J. Morris, and A. K. Webb, Thorax 59:948-951, 2004, http://dx.doi.org/10.1136/thx.2003.017210). B. cenocepacia often possesses innate resistance to multiple antimicrobial classes, making eradication uncommon in established infection (P. B. Davis, Am J Respir Crit Care Med 173:475-482, 2006, http://dx.doi.org/10.1164/rccm.200505-840OE). We report the use of clinafloxacin in a CF patient with advanced B. cenocepacia infection, present pharmacokinetic (PK) data, and discuss the potential therapeutic role of clinafloxacin in patients with this condition.
authors.affiliation: Division of Pulmonary & Critical Care, Maine Medical Center, Portland, Maine, USA.
authors.forename: Akshu
authors.initials: A
authors.lastname: Balwan
authors.affiliation: Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
authors.affiliation: Department of Pharmacy, Maine Medical Center, Portland, Maine, USA.
authors.forename: Minkey
authors.initials: M
authors.lastname: Wungwattana
authors.affiliation: Division of Pulmonary & Critical Care, Maine Medical Center, Portland, Maine, USA jzuckerman@cmamaine.com Valerie.waters@sickkids.ca.
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Zuckerman
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada jzuckerman@cmamaine.com Valerie.waters@sickkids.ca.
authors.forename: Valerie
authors.initials: V
authors.lastname: Waters
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019121:Burkholderia Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D057508:Burkholderia cenocepacia / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000382:microbiology / Q000473:pathology; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications / Q000382:microbiology / Q000473:pathology; D017809:Fatal Outcome; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C057477:clinafloxacin